Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 2, 2023 4:05 PM EDTCompany to present new data at AASLD from Phase 2 chronic hepatitis B and chronic hepatitis delta clinical trials
Company expanding strategic focus to autoimmune diseases and immuno-oncology
Jennifer Towne, Ph.D., appointed as Executive Vice President and Chief Scientific Officer, effective November 6, 2023
Secured new BARDA funding for the development of RNA-delivered monoclonal antibodies
$1.7 billion in cash, cash equivalents and investments as of September 30, 2023
Conference call scheduled for 1:30 p.m. PT / 4:30 p.m. ET, November 2, 2023
SAN FRANCISCO--(BUSINESS WIRE)-- Vir... More
